Avecho Biotechnology Ltd

ASX:AVE (Australia)  
A$ 0.00 (0%) May 28
At Loss
P/B:
1.50
Market Cap:
A$ 9.51M ($ 6.34M)
Enterprise V:
A$ 4.18M ($ 2.79M)
Volume:
-
Avg Vol (2M):
5.12M
Also Trade In:

Business Description

Description
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 31.45
Equity-to-Asset 0.87
Debt-to-Equity 0.03
Debt-to-EBITDA -0.05
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -45.57
Distress
Grey
Safe
Beneish M-Score -6.99
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 40.38
9-Day RSI 42.74
14-Day RSI 44.12
12-1 Month Momentum % -20

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.31
Quick Ratio 8.19
Cash Ratio 6.53
Days Inventory 149.44
Days Sales Outstanding 324.49
Days Payable 322.4

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -25.6
Shareholder Yield % -77.1

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % -9.3
Operating Margin % -1008.03
Net Margin % -726.64
FCF Margin % -672.3
ROE % -93.75
ROA % -70.69
ROIC % -346.26
ROC (Joel Greenblatt) % -874.19
ROCE % -89.96
Years of Profitability over Past 10-Year 1

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 1.5
EV-to-EBIT -1.22
EV-to-EBITDA -1.29
EV-to-Revenue 8.84
EV-to-FCF -1.31
Earnings Yield (Greenblatt) % -81.97
FCF Yield % -33.45

Financials

ASX:AVE's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Avecho Biotechnology Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$) 0.473
EPS (TTM) (A$) -0.001
Beta 1.2
Volatility % 99.88
14-Day RSI 44.12
14-Day ATR (A$) 0.000571
20-Day SMA (A$) 0.003475
12-1 Month Momentum % -20
52-Week Range (A$) 0.003 - 0.009
Shares Outstanding (Mil) 3,169.3

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Avecho Biotechnology Ltd Filings

Filing Date Document Date Form
No Filing Data

Avecho Biotechnology Ltd Stock Events

Financials Calendars
Event Date Price(A$)
No Event Data

Avecho Biotechnology Ltd Frequently Asked Questions

What is Avecho Biotechnology Ltd(ASX:AVE)'s stock price today?
The current price of ASX:AVE is A$0.00. The 52 week high of ASX:AVE is A$0.01 and 52 week low is A$0.00.
When is next earnings date of Avecho Biotechnology Ltd(ASX:AVE)?
The next earnings date of Avecho Biotechnology Ltd(ASX:AVE) is .
Does Avecho Biotechnology Ltd(ASX:AVE) pay dividends? If so, how much?
Avecho Biotechnology Ltd(ASX:AVE) does not pay dividend.

Press Release

Subject Date
No Press Release